Post by Dermatology Times

🗣️📌 BREAKOUT BULLETIN: We're cutting through the noise to bring NPs and PAs the trial results, approvals, and emerging therapies that are actually moving the needle. This week: a long-awaited pediatric indication moves toward FDA action, an oral TYK2 inhibitor posts head-to-head data that could reshape psoriasis prescribing, and early pipeline signals emerge in atopic dermatitis and vitiligo. 🔗 Read more: https://hubs.li/Q04pcx690 #BreakoutBulletin